ASCT: A Viable First-Line Treatment Option for Elderly Multiple Myeloma Patients Without Access to New Drugs

被引：0
|
作者：
Americo, Andre Dias [1 ]
Pittol, Isabella Silva Pimentel [1 ]
Pessoa, Juliana Matos [1 ]
Figueiroa, Hegta [1 ]
Ayoub, Fauze Lutfe [2 ]
de Medeiros Lima, Germano Glauber [2 ]
Zenero, Paula Lucafo [2 ]
Gusmao, Breno [1 ]
Kerbauy, Fabio [1 ]
Amigo Filho, Jose Ulysses [1 ]
Scheinberg, Phillip [1 ]
机构：
[1] Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil
[2] Hosp Municipal Brigadeiro, Sao Paulo, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-331
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [41] First-line treatment strategies for elderly patients with metastatic colorectal cancer
    Meulenbeld, Hielke J.
    Creemers, Geert-Jan
    DRUGS & AGING, 2007, 24 (03) : 223 - 238
  • [42] Challenge of systemic first-line treatment of elderly lung cancer patients
    Ferentinos, K.
    Volmerig, J.
    Nilius, G.
    Jaeger, B.
    Koziorowski, A.
    Stoever, I.
    Christoph, D. C. C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [43] OUTCOME OF AUTOLOGOUS STEM CELLS TRANSPLANTATION (ASCT) IN COMPARISON WITH NEW DRUG-BASED REGIMENS AS SALVAGE TREATMENT AFTER FIRST LINE THERAPY WITH SINGLE OR TANDEM ASCT IN MULTIPLE MYELOMA PATIENTS
    Crippa, C.
    Ferrari, S.
    Drera, M.
    Roccaro, A.
    Baushi, L.
    Antoniazzi, F.
    Rossi, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 152 - 153
  • [44] CONSOLIDATION WITH HD- MELPHALAN AND AUTOTRANSPLANT (ASCT) AFTER SECOND-LINE TREATMENT INCREASES RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN MYELOMA PATIENTS RELAPSED AFTER FIRST-LINE ASCT
    Claudia, C.
    Cavallo, F.
    Ferrari, S.
    Cerqui, E.
    Antoniazzi, F.
    Palladino, C.
    Schieppati, F.
    Pagani, C.
    Palumbo, A.
    Rossi, G.
    HAEMATOLOGICA, 2013, 98 : 322 - 322
  • [45] First-line treatment of multiple myeloma in both transplant and non-transplant candidates
    Oriol, Albert
    Abril, Laura
    Ibarra, Gladys
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 685 - 698
  • [46] High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma
    Mark, Tomer M.
    Yadlapati, Sujitha
    Neglyad, Lyubov
    Bourke, Jennifer
    Jayabalan, David
    Rossi, Adriana C.
    Pearse, Roger N.
    Perry, Arthur
    Pekle, Karen
    Pogonowski, Kathleen
    Tegnestam, Linda
    Huang, Xiangao
    Di Liberto, Maurizio
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    BLOOD, 2015, 126 (23)
  • [47] Current status of new drugs for the treatment of patients with multiple myeloma
    Kenealy, M.
    Prince, H. M.
    INTERNAL MEDICINE JOURNAL, 2006, 36 (12) : 781 - 789
  • [48] Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma
    Fiala, Mark A.
    Ailawadhi, Sikander
    Vij, Ravi
    Wildes, Tanya M.
    BLOOD, 2017, 130
  • [49] Place of autologous hematopoietic stem cell transplantation in the first-line treatment of multiple myeloma?
    Stocker, Nicolas
    HEMATOLOGIE, 2020, 26 (04): : 183 - 183
  • [50] Real World Results of Multiple Myeloma Patients - Low Mortality Rate from First-Line to Second-Line Treatment
    Keil, Felix
    Attalla, Petra
    Seebacher, Adelheid
    Burger, Sabine
    Koller, Elisabeth
    Sliwa, Thamer
    Laschan, Claudia
    Krauter, Andreas
    Pfeilstoecker, Michael
    Fillitz, Michael
    BLOOD, 2022, 140 : 12598 - 12599
12345